WILLIAM JEFFERY EDENFIELD, MD

Plain English
This study looked at the safety and dosage of two cancer treatments, peposertib and avelumab, in patients with advanced solid tumors, both alone and with radiation therapy. Researchers found that doses of peposertib up to 200 mg taken twice daily or 250 mg taken once daily were generally safe for patients, though they did not see significant tumor shrinkage in most cases. This research is important because it helps determine potential treatment combinations for patients with hard-to-treat cancers, even if they did not show major results in this study. Who this helps: Patients with advanced solid tumors.

Plain English
This study examined a new drug called BMS-986158 in patients with advanced solid tumors to see how safe it is and how well it works. Out of 83 patients, diarrhea and low platelet counts were the most common side effects, affecting 43% and 39% of patients, respectively. Some patients had stable disease, meaning their cancer did not progress for a while, and two experienced a partial response to the treatment. This research is important because it shows that BMS-986158 may be a promising option for treating certain types of advanced cancer. Who this helps: This helps cancer patients seeking new treatment options.

Plain English
This study looked at the effects of a new treatment called Rovalpituzumab tesirine (Rova-T) on heart function in patients with small cell lung cancer (SCLC), a serious disease with limited treatment options. After giving the drug to 46 patients, researchers found that it did not cause harmful changes in heart rhythm, as the QT interval, an important measurement for heart health, remained stable. While 24% of patients saw some improvement in their cancer, the study confirmed that Rova-T is safe for the heart in the doses tested. Who this helps: Patients with small cell lung cancer and their doctors.

Plain English
This study looked at the impact of a drug called trilaciclib given before chemotherapy on patients with small cell lung cancer. The findings showed that patients taking trilaciclib needed less supportive care, such as blood transfusions or specific growth-factors to boost their blood cell counts, compared to those who did not take the drug: 28.5% needed growth factors versus 56.3% in the non-trilaciclib group, and 14.6% required blood transfusions compared to 26.1%. This is important because it suggests that trilaciclib can help lessen the side effects of chemotherapy, making treatment easier for patients. Who this helps: This helps patients undergoing chemotherapy for small cell lung cancer.

Plain English
This study examined two different formulations of a cancer medication called CC-486, specifically looking at how well a single 300 mg tablet works compared to two 150 mg tablets. Researchers found that the two forms were equivalent in how well the body absorbed the medication, with only minor differences when patients ate food; the one-tablet version was absorbed slightly slower when food was present but still worked effectively. This matters because it shows that patients can take CC-486 in a simpler form without losing its effectiveness, which can improve their treatment experience. Who this helps: This benefits cancer patients who need easier medication options.

Plain English
This study looked at how a cancer drug called CC-486 (oral azacitidine) is absorbed by the body and how food affects this process. The researchers corrected some numbers in their previous report, ensuring accurate data for doctors and researchers. Accurate information is crucial because it helps ensure that patients receive the right treatment. Who this helps: This helps doctors and patients by providing reliable data for effective cancer treatment.

Plain English
This study tested a new treatment combination of AMG 820 and pembrolizumab on patients with advanced cancers, including colorectal, pancreatic, and non-small cell lung cancer. Out of 116 patients, 99% experienced side effects, with common issues being fatigue and rash, and only 3% showed meaningful improvement in their condition. This matters because while the treatment was generally safe, it did not provide enough benefits to move forward for further research. Who this helps: This helps doctors and researchers understand the limitations of this treatment combination for cancer patients.

Plain English
This study looked at how effective a drug called avelumab works for patients with advanced breast cancer that hasn't improved with standard treatments. Out of 168 patients, only 3% had a positive response to the treatment, but the response rate was higher at 5.2% for those with a specific type of breast cancer known as triple-negative breast cancer. The findings suggest that patients with certain immune markers in their tumors may respond better to this treatment, which is essential for guiding future therapies. Who this helps: This helps patients with advanced breast cancer and their doctors in understanding treatment options.

Plain English
This study looked at the quality of life of brain tumor survivors who received radiation therapy and were treated with either a drug called donepezil or a placebo for cognitive issues. Out of 198 patients, those with more severe cognitive symptoms at the start of the study experienced benefits in emotional well-being and social health after 12 weeks of donepezil treatment. However, those with fewer cognitive symptoms reported worse overall functioning and more fatigue from the treatment. Who this helps: This benefits brain tumor survivors dealing with cognitive issues after radiation therapy.

Plain English
This study looked at the levels of a protein called PD-L1 in small cell lung cancer (SCLC) tumors to understand how it might affect treatment options. Researchers found that 16.5% of tumor samples showed PD-L1 protein expression, with slightly higher rates in a group with less advanced disease (14.7% and 19.4% using different testing methods). This matters because higher levels of PD-L1 were linked to more immune cells infiltrating the tumor, which could be important for how effectively the cancer can be treated. Who this helps: This helps patients with small cell lung cancer and their doctors in understanding the disease's behavior and treatment possibilities.

Plain English
This study looked at how safe and effective the drug pralatrexate is for patients with advanced solid tumors and lymphoma who have different levels of kidney function. Out of 29 enrolled patients, 27 received at least one dose of pralatrexate. The findings showed that patients with mild or moderate kidney issues could take the usual dose of 30 mg without problems, while those with severe kidney impairment should only take 15 mg to avoid higher toxicity risks. Who this helps: This research benefits patients with cancer and kidney impairment.